{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:49:02Z","timestamp":1761238142651},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T00:00:00Z","timestamp":1425945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Current therapies for multiple sclerosis (MS), a chronic autoimmune neuroinflammatory disease, mostly target general cell populations or immune molecules, which may lead to a compromised immune system. A more directed strategy would be to re-enforce tolerance of the autoaggressive T cells that drive tissue inflammation and injury. In this study, we have investigated whether the course of experimental autoimmune encephalomyelitis (EAE) in mice and marmosets can be altered by a potent tolerizing fusion protein. In addition, a multi-parameter immunological analysis was performed in marmosets to assess whether the treatment induces modulation of EAE-associated cellular and humoral immune reactions. The fusion protein, CTA1R9K-hMOG10\u201360-DD, contains a mutated cholera toxin A1 subunit (CTA1R9K), a dimer of the Ig binding D region of Staphylococcus aureus protein A (DD), and the human myelin oligodendrocyte glycoprotein (hMOG) sequence 10\u201360. We observed that intranasal application of CTA1R9K-hMOG10\u201360-DD seems to skew the immune response against myelin oligodendrocyte glycoprotein (MOG) towards a regulatory function. We show a reduced number of circulating macrophages, reduced MOG-induced expansion of mononuclear cells in peripheral blood, reduced MOG-induced production of interleukin (IL)-17A in spleen, increased MOG-induced production of IL-4 and IL-10 and an increased percentage of cells expressing programmed cell death-1 (PD-1) and CC chemokine receptor 4 (CCR4). Nevertheless, the treatment did not detectably change the EAE course and pathology. Thus, despite a detectable effect on relevant immune parameters, the fusion protein failed to influence the clinical and pathological outcome of disease. This result warrants further development and improvement of this specifically targeted tolerance inducing therapy.<\/jats:p>","DOI":"10.1111\/cei.12487","type":"journal-article","created":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T04:15:04Z","timestamp":1415852104000},"page":"28-39","source":"Crossref","is-referenced-by-count":8,"title":["Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10\u201360 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model"],"prefix":"10.1093","volume":"180","author":[{"given":"Y S","family":"Kap","sequence":"first","affiliation":[{"name":"Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands"},{"name":"MS Centre ErasMS, Rotterdam, The Netherlands"},{"name":"Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"van Driel","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Arends","sequence":"additional","affiliation":[{"name":"Preclinical Department, Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Rouwendal","sequence":"additional","affiliation":[{"name":"Department of New Molecular Entities, Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Verolin","sequence":"additional","affiliation":[{"name":"Toleranzia, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Blezer","sequence":"additional","affiliation":[{"name":"Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Lycke","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B A","family":"'t Hart","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands"},{"name":"MS Centre ErasMS, Rotterdam, The Netherlands"},{"name":"Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Neuroscience, University Medical Center, University Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,3,10]]},"reference":[{"key":"2021122010130523100_cei12487-bib-0001","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/eji.1830271144","article-title":"Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions","volume":"27","author":"Kerlero de Rosbo","year":"1997","journal-title":"Eur J Immunol"},{"key":"2021122010130523100_cei12487-bib-0002","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0165-5728(03)00048-1","article-title":"Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls","volume":"137","author":"Van der Aa","year":"2003","journal-title":"J Neuroimmunol"},{"key":"2021122010130523100_cei12487-bib-0003","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.4049\/jimmunol.172.6.3893","article-title":"Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis","volume":"172","author":"Bielekova","year":"2004","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1440-1711.1998.00750.x","article-title":"A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit","volume":"76","author":"Agren","year":"1998","journal-title":"Immunol Cell Biol"},{"key":"2021122010130523100_cei12487-bib-0005","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.4049\/jimmunol.162.4.2432","article-title":"Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity","volume":"162","author":"Agren","year":"1999","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0006","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.158.8.3936","article-title":"Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit","volume":"158","author":"Agren","year":"1997","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0007","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/art.24566","article-title":"Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis","volume":"60","author":"Hasselberg","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021122010130523100_cei12487-bib-0008","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.4049\/jimmunol.0901445","article-title":"ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization","volume":"184","author":"Hasselberg","year":"2010","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0009","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11481-013-9487-z","article-title":"Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species","volume":"8","author":"Haanstra","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"2021122010130523100_cei12487-bib-0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4049\/jimmunol.165.2.1093","article-title":"Myelin\/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule","volume":"165","author":"Brok","year":"2000","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0011","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4049\/jimmunol.180.3.1326","article-title":"Fast progression of recombinant human myelin\/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells","volume":"180","author":"Kap","year":"2008","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0012","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/NEN.0b013e3181d5d053","article-title":"Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete Freund adjuvant","volume":"69","author":"Jagessar","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"2021122010130523100_cei12487-bib-0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/eji.201141863","article-title":"Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG (34-56) peptide in incomplete adjuvant","volume":"42","author":"Jagessar","year":"2012","journal-title":"Eur J Immunol"},{"key":"2021122010130523100_cei12487-bib-0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000109937","article-title":"Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12\/23p40 in a nonhuman primate model of multiple sclerosis","volume":"5","author":"'t Hart","year":"2008","journal-title":"Neurodegener Dis"},{"key":"2021122010130523100_cei12487-bib-0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.yhbeh.2009.12.004","article-title":"Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata","volume":"57","author":"Smith","year":"2010","journal-title":"Horm Behav"},{"key":"2021122010130523100_cei12487-bib-0016","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.4049\/jimmunol.169.10.5415","article-title":"Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs","volume":"169","author":"de Vos","year":"2002","journal-title":"J Immunol"},{"key":"2021122010130523100_cei12487-bib-0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/nbm.1085","article-title":"Quantitative MRI\u2013pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis","volume":"20","author":"Blezer","year":"2007","journal-title":"NMR Biomed"},{"key":"2021122010130523100_cei12487-bib-0018","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1538\/expanim.62.159","article-title":"An overview of models, methods, and reagents developed for translational autoimmunity research in the common marmoset (Callithrix jacchus)","volume":"62","author":"Jagessar","year":"2013","journal-title":"Exp Anim"},{"key":"2021122010130523100_cei12487-bib-0019","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ\u2013PCR) \u2013 a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"2021122010130523100_cei12487-bib-0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/intimm\/dxp019","article-title":"Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines","volume":"21","author":"Kondo","year":"2009","journal-title":"Int Immunol"},{"key":"2021122010130523100_cei12487-bib-0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J Exp Med"},{"key":"2021122010130523100_cei12487-bib-0022","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4049\/jimmunol.170.2.711","article-title":"Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses","volume":"170","author":"Bennett","year":"2003","journal-title":"J Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12487","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/180\/1\/28\/41791496\/cei12487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/180\/1\/28\/41791496\/cei12487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T03:17:13Z","timestamp":1689650233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/180\/1\/28\/6422092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,10]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,3,10]]},"published-print":{"date-parts":[[2015,3,10]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12487","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,4]]},"published":{"date-parts":[[2015,3,10]]}}}